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Abstract
The clinical spectrum of diseases associated with 
monoclonal gammopathies is wide and they are most 
commonly the consequence of renal deposition of 
monoclonal immunoglobulin or its components. The 
differential diagnosis is difficult and renal biopsy is 
essential. To distinguish many of these pathologies is 
necessary to use techniques that are not always avai-
lable, even in tertiary central hospitals. This review will 
discuss the clinical presentation, pathologic features, 
treatment, prognosis and common diagnostic difficulties 
of these entities.
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Core tip: Monoclonal gammopathy of renal significance 
is a wide group of kidney diseases. We discuss the most 
common diagnostic difficulties and suggest an algorithm 
for clinical approach. Screening for monoclonal immuno-
globulin and an appropriate hematologic workup are 
fundamental and, sometimes a difficult challenge. 
Kidney biopsy is required to determine the exact nature 
of the lesion and to evaluate the severity of renal dis-
ease. Therefore, clinical and pathologic features are also 
discussed.
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INTRODUCTION
The term monoclonal gammopathy of renal significance 
(MGRS) is a recent concept, introduced in 2012, to 
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distinguish the nephropathic nature of these diseases 
from the truly benign monoclonal gammopathy of 
undetermined significance[1-3]. 
Renal damage is caused by the deposition of 
secreted monoclonal immunoglobulin (MIg) or its frag-
ments, produced by a B-cell or plasma cell clone. They 
are heterogeneous in nature and are not always related 
to the presence of a detectable M component in serum 
and/or urine. 
 The immunoglobulin (Ig) deposits associated to 
MGRS can be classified into two categories (Table 
1). The first is characterized by organized deposits: 
Immunoglobulin related amyloidosis, fibrillar glomeru-
lonephritis, immunotactoid and type I cryoglobulinemic 
glomerulonephritis. The second disease category is 
characterized by non-organized electro-dense granular 
deposits in clinical pathological entities as MIg deposition 
disease, proliferative glomerulonephritis with monoclonal 
IgG deposits and C3 glomerulopathy with monoclonal 
gammopathy. We decided to address only diseases with 
glomerular involvement.
Several mechanisms that induce injury have been 
described, such as deposition and precipitation of MIg 
in the different components of the kidney (glomeruli, 
vessels, interstitium)[4], dysregulation of the comple-
ment pathway by the MIg[5], and the MIg itself acting 
like autoantibodies against complement factor or 
phospholipase A2 receptor[6]. Other mechanisms are 
still unknown. 
Diagnostic workup 
Screening for MIg and an appropriate hematologic 
workup are essential. It should include serum (SPEP), 
urine electrophoresis, immunofixation studies and free 
light-chain assays (FLC) if conventional electrophoresis 
studies are negative. FLC is more sensitive for the 
detection of light chains than urine immunofixation. 
Results may be affected by the presence of renal failure, 
but a Kappa(κ)/lambda(λ) light-chain ratio > 3.0 is 
unlikely to be due to renal insufficiency alone.
MIg may be undetectable by these methods 
reflecting the “small” size of the underlying clone. 
It is mandatory to characterize the clone by bone 
marrow aspirate and biopsy, to establish the therapeutic 
strategy. 
The M protein in light chain deposition disease can 
be identified by FLC, however only 25%-76% of the 
cases can be identified by SPEP or immunofixation 
studies[2,4]. In light chain amyloidosis, SPEP and immuno-
fixation can identify the M protein in 66%-80% of the 
cases and FLC in 76%-88%[2]. 
A review of systems especially renal, cardiac, 
skin and nervous system should be performed when 
evaluating patients with monoclonal gammopathy.
Kidney biopsy is therefore required to determine the 
exact nature of the lesion and severity of renal disease, 
and in most situations, detailed immunofluorescence (IF) 
and electron microscopic (EM) studies are need to allow 
the identification of deposits composition and pattern of 
organization (Figure 1). 
Hence, with such difficulties diagnosing and classi-
fying these diseases, it is easy to understand that 
misdiagnosis and delayed treatment can occur, with 
an adverse impact on renal and patient prognosis. In 
this review we discuss the diagnostic approach, clinical 
and pathologic features of MGRS lesions related to Ig 
deposits and the diagnostic difficulties posed in the 
clinical practice.
ORGANIZED FIBRILLAR IG DEPOSITS
Immunoglobulin related amyloidosis
Free Ig subunits secreted by a single clone of B cells, 
mostly light chains (λ or κ isotype), are the cause of 
the most common and severe amyloidosis affecting 
the kidney. The fibrils in Ig light chain (AL) amyloidosis 
are derived from the variable region of λ light chains 
in approximately seventy-five percent of cases, and κ 
in the remaining[7,8]. The involvement of an Ig heavy 
chain in amyloidosis (heavy chain only - AH; and heavy 
chains and light chains - AHL amyloidosis) remains 
extremely rare. 
By light microscopy, amyloid deposits are amorphous 
and acellular pale eosinophilic material. The glomeruli 
may show massive amyloid deposits, typically without 
increase in cellularity. Amyloid deposits may also involve 
arterioles, arteries, interstitium and tubules. Definitive 
diagnosis is made by Congo red stain detecting apple-
green birefringence under polarized light[8,9]. By EM, 
amyloid appears as nonbranching fibrils with a diameter 
of 8 to 10 nm[9].
On IF microscopy, the staining for a single AL 
with negativity for Ig heavy chain, is diagnostic of AL. 
Deposition of the variable region explains why IF micro-
scopy with anti-λ and anti-κ light chain antibodies is 
often weakly positive[10]. It is important to be aware that 
the absence of reactivity for either heavy or light chain 
does not rule out AL/AH/AHL disease[9].
Problematic amyloid cases, such as those with 
equivocal IF (which is more frequent with heavy chains 
than with light chains) can be accurately typed by laser 
  Organized immunoglobulin deposits
     Fibrillar deposits Immunoglobulin related amyloidosis
Fibrillar glomerulonephritis
     Microtubular deposits Immunotactoid glomerulopathy
Type I cryoglobulinemic glomerulo-
nephritis
  Non-organized immunoglobulin deposits
     Monoclonal Light chain deposition disease
     Immunoglobulin Light and heavy chain deposition disease
     Deposition disease Heavy deposition disease
  Proliferative glomerulonephritis with monoclonal IgG deposits
  C3 glomerulopathy with monoclonal gammopathy
Table 1  Monoclonal gammopathy of renal significance 
associated renal lesions
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microdissection and mass spectrometry. This methods 
can identify the type of renal amyloidosis in more than 
97% of cases, and can distinguish it from non-amyloid 
fibrillar glomerulonephritis[8,11,12]. 
The majority of patients will have a detectable 
serum and/or urinary M protein. All patients require 
immunofixation of serum and urine and FLC ratio. 
AL/AH/AHL are associated with a higher degree 
of proteinuria and a higher frequency of nephrotic 
syndrome compared with the other types of amyloido-
sis[12]. On presentation renal impairment may be 
present. 
The goal of current treatment approaches for AL 
amyloidosis is to eradicate the clonal plasma cells that 
produce the amyloidogenic light chain. The prognosis 
of AL amyloidosis has improved substantially during the 
past decade with the increasing use of aggressive anti-
plasma cell treatment[9]. 
Fibrillary glomerulonephritis
Fibrillary glomerulonephritis (FGN) is a rare primary 
glomerular disease. The fibrillar deposits have larger 
thickness than amyloid and are Congo red negative[13,14]. 
However, size alone, is an insufficient criterion for 
the diagnosis[13]. Light microscopy typically shows 
mesangial proliferation and a membranoproliferative 
glomerulonephritis (MPGN) pattern. The fibrils are 
deposited in the mesangium, glomerular basement 
membranes, or both. Tubular or interstitial deposits 
are rare. On IF, polyclonal glomerular Ig deposits 
(typically IgG, and light chains) are more common than 
monotypic glomerular deposits[15]. Occasionally staining 
for IgG may occur in a membranous pattern and IgG4 is 
the dominant subclass. The mesangial staining suggests 
the specific diagnosis, confirmed by negative Congo red 
stain and by EM. The EM findings show the presence of 
randomly aligned fibrils that resemble amyloid fibrils but 
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Figure 1  Diagnostic work up. 1New sensitive method for early detection of amyloidosis in humans[36]. AH: Immunoglobulin heavy chain; AHL: Immunoglobulin 
heavy and light chain; AL: Immunoglobulin light chain; C3GN: C3 glomerulonephritis; DDD: Dense deposits disease; EM: Electronic microscopy; EP: Electrophoresis; 
FGN: Fibrillary glomerulonephritis; FLC: Free light chain assay; GN: Glomerulonephritis; GP: Glomerulopathy; IF: Immunofluorescence; Ig: Immunoglobulin; ITG: 
Immunotactoid glomerulonephritis; LC: Light chain; LM: Light microscopy; MG: Monoclonal gammopathy; MIDD: Monoclonal immunoglobulin deposition disease; 
MPGN: Membranoproliferative glomerulonephritis; PGNMID: Proliferative glomerulonephritis with monoclonal immunoglobulin deposits.
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are larger.
In a case series report, one third of the cases occur-
red in patients with history of malignancy (most com-
monly carcinoma) or autoimmune diseases (most com-
monly Crohn’s disease, systemic lupus, Graves’ disease, 
and idiopathic thrombocytopenic purpura)[16]. These cases 
should not be considered MGRS. In the same case 
series[16], 11% stained for IgG and light chains, which 
can lead to believe that the FGN is also a type of MGRS. 
M-spike was detected by SPEP/immunofixation in only 
16% of 61 patients with fibrillary glomerulonephritis 
from a case series of a single medical center[16].
Clinically, FGN most often presents in middle aged 
to older patients. Patients typically present with pro-
teinuria, 50% within nephrotic range, with or without 
renal insufficiency, hematuria or hypertension[15-17]. 
The outcome is frequently poor, progression to end-
stage renal disease occurs in approximately half of the 
patients within years[15-17].
The differential diagnosis between other MPGN can 
be difficult without EM, which can delay the treatment 
targeted to the B cell or plasma cell clone. However 
an optimal treatment are yet to be demonstrated 
and prospective and controlled studies are needed to 
determine the appropriated therapeutic regimen. There 
is an ongoing phase 2 clinical trial to evaluate Rituximab 
as a treatment option[18]. Recurrence (20%) in transplant 
allograft has been reported[15].
ORGANIZED MICROTUBULAR IG 
DEPOSITS
Immunotactoid glomerulopathy
Immunotactoid (microtubular) glomerulopathy (ITG) 
is a glomerular disease characterized by the presence 
of Congo red negative organized glomerular deposits 
generally limited to the glomerulus, stain by IF for IgG (in 
most cases monoclonal) and complement. Renal biopsy 
shows lobular MPGN or membranous pattern[13,15,19]. 
The microtubular structure often measure > 30 nm 
in diameter by EM and are often organized in parallel 
arrays[17]. ITG occurs in an older population and is 
typically presented as a nephrotic syndrome. Hypocom-
plementemia is common[15,17].
Underlying hematologic malignancy is frequent, and 
the most common is chronic lymphocytic leukemia (in 
contrast to AL amyloidosis and monoclonal immuno-
globulin deposition disease in which the most common 
is myeloma)[13,19]. Lymphoplasmacytic lymphoma and 
MGRS are also common[13,19]. 
FGN and ITG can be overlooked when EM is not 
performed. Even with EM, the diagnosis can be difficult in 
a variety of circumstances: When fibrils are subepithelial; 
when they have an atypical ultrastructural appearance; 
when deposits of cryoglobulins are microtubular and 
indistinguishable from these; and when fibrils or micro-
tubules are of a smaller admeasured size[17].
Type I cryoglobulinemic glomerulonephritis
Cryoglobulinemia is defined as the presence of circulating 
immunoglobulins that precipitate with cold temperature 
and dissolve with rewarming. Type I cryoglobulinemia 
consist of a single monoclonal immunoglobulin (usually 
of IgG or IgM class), while types II and III are mixed 
cryoglobulinemias, with a monoclonal component in 
type II and only polyclonal immunoglobulins in type 
III[20,21]. By light microscopy typical features are mem-
branoproliferative or endocapillary proliferative glomeru-
lonephritis with intraluminal periodic acid-Schiff  positive 
(hyaline-like) deposits. IF microscopy demonstrates the 
presence of IgM and IgG as well as complement com-
ponents. On EM, deposits are predominantly subendo-
thelial and intracapillary. They may have a vague 
short fibrillar substructure, and sometimes a tubular 
configuration.
Type I cryoglobulin is associate with plasma cell 
dyscrasias or B-cell lymphoproliferative disorders 
(multiple myeloma, Waldenstrom macroglobulinemia, 
chronic lymphocytic leukemia, B-cell non-Hodgkin 
lymphoma, MGRS, and hairy cell leukemia)[20]. Occur-
rence of cutaneous involvement (palpable purpura) is 
frequent and neurologic manifestations can vary from 
pure sensory axonopathy to mononeuritis multiplex[20]. 
Hypocomplementemia is not as frequent as in type II 
cryoglobulinemia[21]. 
The treatment of this entity is primarily directed to 
the underlying hematologic malignancy[20].
NON-ORGANIZED IG DEPOSITS
Monoclonal immunoglobulin deposition disease
In clinical and pathologic terms, light-chain, light and 
heavy chain, and heavy chain deposition disease (LCDD, 
LHCDD, HCDD, respectively) are similar and may 
therefore be referred as monoclonal immunoglobulin 
deposition disease (MIDD)[4,22]. The majority of kidney 
diseases in MIDD are secondary to deposition of light 
chains (κ in most cases) instead of heavy chains or 
intact Ig[23]. These forms differ from amyloidosis in that 
the deposits lack affinity for Congo red and do not have 
a fibrillar organization. 
Usually they show nodular sclerosing lesions and 
thickening of tubular basement membranes on light 
microscopy; a membranoproliferative pattern has also 
been described. Diffuse linear staining of monoclonal 
light/heavy chains along the glomerular and tubular 
basement membranes is shown on IF and punctate 
dense deposits along the glomerular and tubular 
basement membranes on EM[4,24].
The deposits in HCDD are composed of the Ig heavy 
chain, which typically lacks the first constant domain 
(CH1). IgD deposition disease was recently described 
based on laser microdissection and mass spectrometry 
in which the IF studies were negative for Ig deposits[25].
MIDD is typically diagnosed in the sixth decade, in 
the presence of renal insufficiency and proteinuria, often 
Correia SO et al . MGRS: Diagnostic workup
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accompanied by nephrotic syndrome or hypertension. 
It can occur in the absence of a detectable malignant 
process, even after prolonged follow-up[4]. In some 
case series clinical evidence of dysproteinemia was 
frequent, with myeloma and MGRS being described[4,24]. 
Treatment of the underling dysproteinemia should be 
considered, and studies have shown that chemotherapy 
and stem cell transplantation are an effective therapy 
for renal dysfunction in MIDD[24,26,27]. Recurrence in 
transplant allograft has been reported[24].
Proliferative glomerulonephritis with monoclonal IgG 
deposits
Monoclonal gammopathy is an important cause of mem-
branoproliferative glomerulonephritis pattern, which 
is an immune complex-mediated glomerulonephritis 
characterized by subendothelial and mesangial immune 
complexes deposition. Nars and collegues, described 
this entity of proliferative glomerulonephritis associated 
with monoclonal IgG deposition[28]. A similar entity 
with deposition of monoclonal IgM or IgA has been 
described[29,30].
IF demonstrates deposits restricted to the glomeru-
lus that stained for a single light-chain isotype and a 
single heavy-chain subtype, most commonly IgG3[31]. 
EM reveals mesangial, subendothelial and intrame-
mbranous granular non-organized deposits.
In cases of endocapillary proliferative or mem-
branoproliferative glomerulonephritis in which the 
deposits stain for IgG and a single light chain, differen-
tial diagnoses should be made with type 1 cryoglo-
bulinemic glomerulonephritis, and ITG[28]. The diagnosis 
of ITG is established by EM and type 1 cryoglobulinemic 
glomerulonephritis should be excluded by clinical 
features. A specific clone was identified in 5% to 25% 
in some case series[28,31].
Proliferative glomerulonephritis with monoclonal 
IgG deposits is typically presented with proteinuria, 
variable degrees of hematuria, renal insufficiency and 
hypertension. Hypocomplementemia (mostly of the C3 
component) is frequent. 
Treatment recommendations are based on clinical 
experience with small numbers of patients. Immuno-
suppressive therapy have been used with variable 
outcomes[32].
C3 glomerulopathy with monoclonal gammopathy
C3 glomerulopathy is characterized by the accumulation 
of complement component C3 in glomeruli caused by 
abnormal control of complement activation, degradation 
or deposition.
On light microscopy it could show a variety of appear-
ances: Mesangial proliferation, membranoproliferative 
pattern, endocapillary proliferation or crescent formation. 
C3 glomerulonephritis (C3GN) and dense deposit 
disease (DDD) are its subtypes and can be distinguished 
by EM. DDD is characterized by replacement of the 
basement membrane by highly electron dense deposits. 
C3GN is characterized by mesangial, subendothelial and/
or subepithelial granular deposits that are less electron 
dense[33,34].
C3 glomerulopathy could be an unusual complication 
of plasma cell dyscrasia[35]. Monoclonal protein (which 
in this case, does not deposit in the glomeruli) can 
interfere with complement regulating proteins such as 
factor H, and act as a C3 nephritic factor resulting in 
a pathological activation of the alternative pathway of 
complement.
The clinical presentation is usually with hematuria, 
proteinuria with or without renal insufficiency. Serum C3 
levels can be low. 
The optimal treatment remains undefined. There 
have been contradictory reports in published literature, 
about the efficacy of treatment based on glucocorticoid, 
mycophenolate mofetil, and rituximab[5,33]. There 
are many ongoing innovative approaches using eculi-
zumab[33]. Studies have been reported in which the 
use of eculizumab in dense deposit disease and C3 
glomerulonephritis resulted in proteinuria reduction 
and/or serum albumin normalization and/or creatinine 
decrease[33].
The risk for recurrence of C3 glomerulopathy is high, 
but one must take into account that all these results are 
based on small data sets[33].
In order to facilitate and summarize the clinical 
approach of the different entities mentioned above, 
we decided to build up a diagnostic work up algorithm, 
which we here propose (Figure 1).
CONCLUSION
Monoclonal immunoglobulin can cause a variety of 
renal diseases resulting from the direct renal deposition 
and precipitation or, from an indirect mechanism, for 
example, via dysregulation of the complement pathway.
In this group of renal disorders the differential dia-
gnosis can be a clinical challenge and that’s why we 
considered that an algorithm for the approach has to be 
developed and improved. 
A common clinical challenge begins with the identifi-
cation of the underlying clone. Standardized diagnostic 
evaluations need to be carried out as summarize above. 
Diagnosis requires a detailed hematologic evaluation 
and kidney biopsy. Morphologic alterations on light 
microscopy and immunofluorescence often need to be 
integrated with the changes on electron microscopy.
The lack of experience in dealing with these dis-
eases can delay treatment. Increased cognizance and 
appreciation of this clinical-pathological entity and 
associated treatment options may improve patient 
outcomes.
Successful treatment is based on chemotherapy 
that should be adapted to the underlying clone and 
renal function. A multidisciplinary team consisting of 
nephrologists and hematologists should take respon-
sibility for an individualized therapeutic approach as no 
standardized treatments based on prospective studies 
exist.
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